1 Faculty of Medical and Health Sciences, University of Auckland, Park Road, Grafton, 1142 Auckland, New Zealand.
3 Department of Microbiology and Immunology, University of Otago, 720 Cumberland St, Dunedin 9016 New Zealand.
Benef Microbes. 2019 Feb 8;10(1):5-17. doi: 10.3920/BM2017.0191. Epub 2018 Dec 21.
Probiotic Lactobacillus rhamnosus HN001 given in early life has been shown to reduce infant eczema risk, but its effect on gut microbiota development has not been quantitatively and functionally examined. The aim of this study was to investigate the impact of early life probiotic exposure on the composition and functional capacity of infant gut microbiota from birth to 2 years considering the effects of age, delivery mode, antibiotics, pets and eczema. We performed shotgun metagenomic sequencing analysis of 650 infant faecal samples, collected at birth, 3, 12, and 24 months, as part of a randomised, controlled, 3-arm trial assessing the effect of L. rhamnosus HN001, Bifidobacterium animalis subsp. lactis HN019 supplementation on eczema development in 474 infants. There was a 50% reduced eczema risk in the HN001 probiotic group compared to placebo. Both mothers (from 35 weeks gestation until 6 months post-partum if breastfeeding) and infants (from birth to 2 years) received either a placebo or one of two probiotics, L. rhamnosus HN001 (6×10 cfu), or B. animalis subsp. lactis HN019 (9×10 cfu). L. rhamnosus HN001 probiotic supplementation was associated with increased overall glycerol-3 phosphate transport capacity and enrichment of L. rhamnosus. There were no other significant changes in infant gut microbiota composition or diversity. Increased capacity to transport glycerol-3-phosphate was positively correlated with relative abundance of L. rhamnosus. Children who developed eczema had gut microbiota with increased capacity for glycosaminoglycan degradation and flagellum assembly but had no significant differences in microbiota composition or diversity. Early life HN001 probiotic use is associated with both increased L. rhamnosus and increased infant gut microbiota functional capacity to transport glycerol-3 phosphate. The mechanistic relationship of such functional alteration in gut microbiota with reduced eczema risk and long-term health merits further investigation.
在生命早期给予益生菌鼠李糖乳杆菌 HN001 已被证明可降低婴儿湿疹的风险，但它对肠道微生物群发育的影响尚未进行定量和功能检测。本研究的目的是调查生命早期益生菌暴露对婴儿肠道微生物群组成和功能能力的影响，从出生到 2 岁，同时考虑年龄、分娩方式、抗生素、宠物和湿疹的影响。我们对 650 名婴儿粪便样本进行了 shotgun 宏基因组测序分析，这些样本是在出生、3、12 和 24 个月时收集的，作为一项随机、对照、3 臂试验的一部分，该试验评估了 L. rhamnosus HN001 和 Bifidobacterium animalis subsp. lactis HN019 补充剂对 474 名婴儿湿疹发展的影响。与安慰剂组相比，HN001 益生菌组湿疹风险降低了 50%。母亲（从 35 周妊娠到产后 6 个月，如果母乳喂养）和婴儿（从出生到 2 岁）都接受了安慰剂或两种益生菌中的一种，即 L. rhamnosus HN001（6×10 cfu）或 B. animalis subsp. lactis HN019（9×10 cfu）。L. rhamnosus HN001 益生菌补充剂与总体甘油-3-磷酸转运能力增加和 L. rhamnosus 富集有关。婴儿肠道微生物群组成或多样性没有其他显著变化。甘油-3-磷酸转运能力的增加与 L. rhamnosus 的相对丰度呈正相关。发生湿疹的儿童肠道微生物群具有增加的糖胺聚糖降解和鞭毛组装能力，但在微生物群组成或多样性方面没有显著差异。生命早期 HN001 益生菌的使用与 L. rhamnosus 的增加和婴儿肠道微生物群甘油-3-磷酸转运能力的增加有关。这种肠道微生物群功能改变与湿疹风险降低和长期健康的机制关系值得进一步研究。
